Reports from the Hungarian capital Budapest say that the retail price ofsubsidized drugs in the country may rise by an average 13%-14% in 1997, compared with the originally planned 8.5% increase, according to MTI Econews.
Changes may also be expected in drug price subsidies, said Mihaly Kokeny, a nominee for the position of Minister of Welfare. The 1997 budget bill in Hungary allocates 85.58 billion forint ($523 million) for drug price subsidies. However, drug prices may not be raised by more than the projected rate of inflation of 18% in 1997. The officially-regulated price margin for drug retailers is now 17.17% but this could go to over 18% in 1997.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze